Table 1 Characteristics of the studies included in the systematic review of progesterone supplementation in HRT-FET
From: Preparation of the endometrium for frozen embryo transfer: an update on clinical practices
Source | Design | Sample size | Progesterone route | Progesterone dose corresponding to route | Day of embryo transfer | Outcomes |
|---|---|---|---|---|---|---|
Wang, Y., et al. (2015) | RCT | 1500 | VG P(gel) + oral DYD IM P + D | 90 mg/d + 20 mg/d 40 mg/d + 20 mg/d | Day 3 | n.s. |
Devine, et al. (2018) Interim analysis | RCT | 645 | VG P(tablet) vs. IM P vs. VG (tablet) + IM P | 200 mg/d 50 mg/d 200 mg×2 /d + 50 mg/e 3rd day | Day 5 afternoon Day 5 afternoon Day 6 afternoon | OPR; P＜0.0001 31% vs. 47% vs. 50%; |
Devine, et al. (2021) Final analysis | RCT | 1060 | VG P(tablet) vs. IM P vs. VG (tablet) + IM P | 200 mg/d 50 mg/d 200 mg×2 /d + 50 mg/e 3rd day | Day 5 afternoon Day 5 afternoon Day 6 afternoon | LBR; P＜0.0001 27% vs. 44% vs. 46%; |
Jiang, L., et al. (2019) | Retrospective cohort | 3013 | IM P + oral DYD vs. VG P (gel) + oral DYD | 60 mg /d + 10 mg×3 /d 90 mg×2 /d + 10 mg×3 /d | Day 4 or 6 | LBR; P＜0.028 40.8% vs. 45% |
Liu Y and Wu Y (2020) | Retrospective cohort | 856 | IM P + oral DYD vs. VG P (gel) + oral DYD | 60 mg /d + 30 mg /d 90 mg/d + 30 mg /d | Day 2 or 3 | n.s. in LBR or neonatal outcomes |
Turkgeldi, et al. (2020) | Retrospective cohort | 214 | SC P vs. VG P (8% gel) | 25 mg×2 /d 90 m×2 /d | Day 6 | n.s. |
Vuong, et al. (2021) | Prospective cohort study | 1364 | VG P(tablet) + oral DYD vs. VG P (tablet) | 400 mg×2 /d + 10 mg×2 /d 400 mg×2 /d | Day 4 or 6 | LBR; P = 0.042 46.3% vs. 41.3% |
Pabuccu, et al. (2022) | RCT | 151 | oral DYD vs. VG P (gel) vs. IM P | 20 mg×2 /d 90 mg×2 /d 50 mg×2 /d | 5 days of P | n.s. |